Outset Medical, Inc.

Outset Medical, Inc. announced that its Compensation Committee approved equity awards under the Company’s Inducement Plan for one executive and two non-executive employees. These awards, granted as a material inducement to employment, include restricted stock units (RSUs) and performance-based restricted stock units (PSUs). Derick Elliott, Executive Vice President of Commercial, received 24,000 PSUs, while two non-executive employees received 4,000 RSUs and 10,000 PSUs, respectively. The awards are subject to specific vesting schedules and performance goals.

Outset Medical, Inc. announced that Marc Nash, Executive Vice President, R&D, Operations and Service, will depart from the company effective June 5, 2026. Mr. Nash is leaving to pursue other professional opportunities. The company stated that his departure is not due to any dispute or disagreement with Outset Medical or its management.

Outset Medical, Inc. announced that its Compensation Committee approved equity awards totaling 45,000 restricted stock units (RSUs) to two newly appointed non-executive employees. These awards were granted as a material inducement to employment under the Company's Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a three-year period.

Outset Medical reported its first-quarter 2026 financial results, with net revenue decreasing 6% to $27.9 million. Despite the revenue dip, the company significantly improved its net loss to $19.0 million from $25.8 million in the prior year. Gross margin expanded by over 600 basis points to 43.4%, driven by record product and service gross margins. The company reiterated its full-year 2026 revenue guidance, expressing confidence in its path to profitability.

Outset Medical reported first quarter 2026 financial results, with net revenue decreasing 6% to $27.9 million. Despite the revenue decline, the company achieved significant gross margin expansion, reaching 43.4% on a GAAP basis and 43.8% on a non-GAAP basis, driven by record product and service gross margins. Net loss narrowed to $19.0 million from $25.8 million in the prior-year period, reflecting progress on its path to profitability. The company also reiterated its full-year 2026 revenue and non-GAAP gross margin guidance.

Outset Medical, Inc. announced it will release its financial results for the first quarter 2026 after the close of trading on Thursday, May 7, 2026. On the same day, Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss the financial and operating results.

Outset Medical, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Stockholders as of the April 9, 2026 record date will vote on three proposals: the election of two Class III directors (Brent D. Lang and Karen Prange) for terms expiring in 2029, a non-binding advisory vote on 2025 named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm for 2026. The Board unanimously recommends voting "FOR" all proposals.